Literature DB >> 15917462

Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: correlation with improved attention in rat.

Evelyn K Lambe1, Peter Olausson, Nicole K Horst, Jane R Taylor, George K Aghajanian.   

Abstract

Thalamic projections to prefrontal cortex are important for executive aspects of attention. Using two-photon imaging in prefrontal brain slices, we show that nicotine and the wakefulness neuropeptide hypocretin (orexin) excite the same identified synapses of the thalamocortical arousal pathway within the prefrontal cortex. Although it is known that attention can be improved when nicotine is infused directly into the midlayer of the prefrontal cortex in the rat, the effects of hypocretin on attention are not known. The overlap in thalamocortical synapses excited by hypocretin and nicotine and the lack of direct postsynaptic effects prompted us to compare their effects on a sustained and divided attention task in the rat. Similar to nicotine, infusions of hypocretin-2 peptide into the prefrontal cortex significantly improved accuracy under high attentional demand without effects on other performance measures. We show for the first time that hypocretin can improve attentional processes relevant to executive functions of the prefrontal cortex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917462      PMCID: PMC6724823          DOI: 10.1523/JNEUROSCI.0719-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  28 in total

1.  The impact of 'bursting' thalamic impulses at a neocortical synapse.

Authors:  H A Swadlow; A G Gusev
Journal:  Nat Neurosci       Date:  2001-04       Impact factor: 24.884

2.  Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task.

Authors:  A J Grottick; G A Higgins
Journal:  Behav Brain Res       Date:  2000-12-20       Impact factor: 3.332

3.  Release of hypocretin (orexin) during waking and sleep states.

Authors:  Lyudmila I Kiyashchenko; Boris Y Mileykovskiy; Nigel Maidment; Hoa A Lam; Ming-Fung Wu; Joshi John; John Peever; Jerome M Siegel
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

4.  Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies.

Authors:  A Blondel; D J Sanger; P C Moser
Journal:  Psychopharmacology (Berl)       Date:  2000-04       Impact factor: 4.530

5.  Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas.

Authors:  Huibert D Mansvelder; J Russel Keath; Daniel S McGehee
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

Review 6.  Cognitive effects of nicotine.

Authors:  A H Rezvani; E D Levin
Journal:  Biol Psychiatry       Date:  2001-02-01       Impact factor: 13.382

7.  Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.

Authors:  Y Yoshida; N Fujiki; T Nakajima; B Ripley; H Matsumura; H Yoneda; E Mignot; S Nishino
Journal:  Eur J Neurosci       Date:  2001-10       Impact factor: 3.386

8.  Nicotine-induced attentional enhancement in rats: effects of chronic exposure to nicotine.

Authors:  B Hahn; I P Stolerman
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

9.  Nicotine at concentrations found in cigarette smokers activates and desensitizes nicotinic acetylcholine receptors in CA1 interneurons of rat hippocampus.

Authors:  M Alkondon; E F Pereira; L E Almeida; W R Randall; E X Albuquerque
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

10.  Differential activation of orexin neurons by antipsychotic drugs associated with weight gain.

Authors:  Jim Fadel; Michael Bubser; Ariel Y Deutch
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more
  63 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

2.  The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy.

Authors:  Craig D C Bailey; Mariella De Biasi; Paul J Fletcher; Evelyn K Lambe
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

3.  Hypocretin (orexin) is critical in sustaining theta/gamma-rich waking behaviors that drive sleep need.

Authors:  Anne Vassalli; Paul Franken
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

4.  Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA.

Authors:  Mark G LeSage; Jennifer L Perry; Catherine M Kotz; David Shelley; William A Corrigall
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

Review 5.  Vigilance, alertness, or sustained attention: physiological basis and measurement.

Authors:  B S Oken; M C Salinsky; S M Elsas
Journal:  Clin Neurophysiol       Date:  2006-04-03       Impact factor: 3.708

6.  Reversible inhibition of GABAA receptors by alpha7-containing nicotinic receptors on the vertebrate postsynaptic neurons.

Authors:  Jingming Zhang; Darwin K Berg
Journal:  J Physiol       Date:  2007-01-04       Impact factor: 5.182

Review 7.  The brain hypocretins and their receptors: mediators of allostatic arousal.

Authors:  Matthew E Carter; Jana Schaich Borg; Luis de Lecea
Journal:  Curr Opin Pharmacol       Date:  2009-02       Impact factor: 5.547

Review 8.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

9.  Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine.

Authors:  Ravi K Pasumarthi; Jim Fadel
Journal:  Brain Res Bull       Date:  2008-10-23       Impact factor: 4.077

Review 10.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.